Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BGI Genomics Co's EBITDA for the
three
months ended in Mar. 2026 was ¥-6 Mil. BGI Genomics Co's Revenue for the
three
months ended in Mar. 2026 was ¥809 Mil. Therefore, BGI Genomics Co's EBITDA margin for the quarter that ended in Mar. 2026 was -0.69%.
BGI Genomics Co (SZSE:300676) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BGI Genomics Co EBITDA Margin % Related Terms
BGI Genomics Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BGI Genomics Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:300676 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, BGI Genomics Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BGI Genomics Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BGI Genomics Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BGI Genomics Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGI Genomics Co (SZSE:300676) has a EBITDA Margin % of -0.69% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BGI Genomics Co and its competitors. According to the industry distribution chart, BGI Genomics Co ranks #133 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 65.5%.
Is BGI Genomics Co's EBITDA Margin % too high?
BGI Genomics Co's current EBITDA Margin % is -0.69%. Based on the distribution chart, BGI Genomics Co ranks #133 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, BGI Genomics Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BGI Genomics Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BGI Genomics Co ranks #133 out of 203 companies for EBITDA Margin %. This places BGI Genomics Co in the lower half of its industry. The industry median EBITDA Margin % is 5.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BGI Genomics Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BGI Genomics Co's current EBITDA Margin % is -0.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BGI Genomics Co stock overvalued right now?
Based on GuruFocus' analysis, BGI Genomics Co (SZSE:300676) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.86, compared to a current price of ¥36.83 — trading 9.9% below its estimated fair value. The current EBITDA Margin % is -0.69%. BGI Genomics Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BGI Genomics Co (SZSE:300676), the current EBITDA Margin % is -0.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BGI Genomics Co (SZSE:300676) Overvalued in 2026?
Based on GuruFocus' analysis, BGI Genomics Co stock appears to be undervalued.
The current stock price of ¥36.83 is trading 9.9% below its estimated GF Value™ of ¥40.86.
GuruFocus considers BGI Genomics Co to be Modestly Undervalued.
Key valuation signals for SZSE:300676:
EBITDA Margin %: -0.69%
GF Value™: ¥40.86 vs. price of ¥36.83 (9.9% below fair value)
No single metric tells the full story. See the SZSE:300676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
71GF Score
Get the complete analysis for SZSE:300676
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300676 has been successfully added to your 
